What ketamine and psilocybin can and cannot do in depression
While ketamine is only suitable for acute intervention, owing to the short duration of effect, the effects of psilocybin can last for weeks or even months following administration.
Related Articles
Evening May Be the Best Time for Exercise
New study finds evening exercise for adults who are obese was linked to lower mortality and rates of heart disease.
Oregon Physician Assistants Get Name Change
In June, Oregon PAs will be referred to as Physician Associates, a title change from Physician Assistants being debated nationwide.
New Federal Rule Delivers Workplace Support, Time Off for Pregnant Docs
Newly updated guidelines for the federal Pregnant Workers Fairness Act could help physicians better balance career and family.
Adding Life to Your Patients’ Years
Physician discusses how to help older patients live well, not just longer.
The Obesogenic Environment of Preschool and Day Care | MDedge
Our challenge is to create effective, yet sensitive, strategies to help the educators and caregivers modify their dietary habits behaviors in a way that helps…
Approved Therapy for ALS Is Withdrawn When New Study Shows No Benefit | MDedge
Unlike a first trial of PB&TURSO, which led to regulatory approval of this combination therapy in 2022, a second larger and longer multicenter placebo-controlle
Vaccination regimen effective in preventing pneumonia in MM patients | MDedge
Vaccination was effective despite the expected decrease in immunological response during target and immunotherapy.
Are Women Better Doctors Than Men? | MDedge
Female patients had a significantly lower 30-day mortality rate than male patients, but they fared even better when cared for by female doctors compared with…
Getting Patients With Opioid Use Disorder Started on Buprenorphine in Primary Care
Any DEA-registered PCP can prescribe buprenorphine and should screen for opioid use disorder, presenter says.
Federal Trade Commission Bans Noncompete Agreements, Urges More Protections for Healthcare Workers
But dissenting commissioners dispute the FTC’s authority to broadly ban noncompetes.